Adjuvant Systemic Therapies in Breast Cancer
Adjuvant Systemic Therapies in Breast Cancer
复制标题
DOI：
10.1016/j.suc.2012.12.002
复制
发表时间：
2013-04-01
影响因子：
3.1
通讯作者：
Gonzalez-Angulo, Ana M.
中科院分区：
文献类型：
--
作者：
Hernandez-Aya, Leonel F.;Gonzalez-Angulo, Ana M.
虽然一些女性早期乳腺癌（BC）可以通过局部局部治疗治愈，但高达20%的早期乳腺癌患者最终会经历治疗失败和复发。在改善BC患者临床结果方面取得成功的很大一部分与辅助治疗的标准化使用有关。具有预后价值的肿瘤亚型的识别有助于使用生物学预测因素来确定最有可能对治疗有反应的患者，并最大限度地减少“无反应”患者对治疗副作用的暴露。
Although some women with early breast cancer (BC) may be cured with loco-regional treatment alone, up to 20% of patients with early-stage BC will ultimately experience treatment failure and recurrence. A substantial portion of the success in improving clinical outcomes of patients with BC is related to the standardized use of adjuvant therapies. The identification of tumor subtypes with prognostic value has contributed to the idea of tailoring treatments using biologic predictive factors to identify the patients who will most likely respond to therapy and minimize the exposure of "non-responders" to the side effects of the treatment.